• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cortexyme, Inc. - Common Stock (NQ:CRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.890 (7)
Ask (Size) 1.990 (2)
Prev. Close 1.950
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 36,382,989
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Thursday
July 28, 2022
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves
May 03, 2022
 
Via Benzinga

Performance

More News

Read More
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
July 27, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
July 27, 2022
Via Benzinga
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
July 27, 2022
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
July 27, 2022
From Cortexyme, Inc.
Via Business Wire
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
June 21, 2022
From Cortexyme, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
July 25, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
June 24, 2022
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
June 16, 2022
Via Benzinga
Cortexyme Appoints June Bray to its Board of Directors
June 13, 2022
From Cortexyme, Inc.
Via Business Wire
69 Biggest Movers From Friday
June 06, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
June 01, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
May 31, 2022
Via Benzinga
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
May 20, 2022
From Cortexyme, Inc.
Via Business Wire
Cortexyme Successfully Completes Acquisition of Novosteo
May 20, 2022
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
May 12, 2022
From Cortexyme, Inc.
Via Business Wire
103 Biggest Movers From Yesterday
May 11, 2022
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Via Benzinga
Cortexyme Announces Agreement to Acquire Novosteo
May 10, 2022
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Via Benzinga
NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc.
April 29, 2022
Via SBWire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX
April 05, 2022
From The Rosen Law Firm, P.A.
Via Business Wire
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
March 21, 2022
From Cortexyme, Inc.
Via Business Wire

Frequently Asked Questions

Is Cortexyme, Inc. - Common Stock publicly traded?
Yes, Cortexyme, Inc. - Common Stock is publicly traded.
What exchange does Cortexyme, Inc. - Common Stock trade on?
Cortexyme, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cortexyme, Inc. - Common Stock?
The ticker symbol for Cortexyme, Inc. - Common Stock is CRTX on the Nasdaq Stock Market
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap